ORIC Pharmaceuticals adopts 2022 Inducement Equity Incentive Plan reserving 500,000 shares

Oric Pharmaceuticals, Inc.

Plan adopted March 1, 2022 by Compensation Committee; 500,000 shares of common stock reserved.
Awards limited to new employees as material inducement to hire, per Nasdaq Listing Rule 5635(c)(4).
Terms substantially similar to company's 2020 Equity Incentive Plan.
Adopted without stockholder approval; approved by independent directors.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.